FDA clears troculeucel for expanded access program

FDA clears troculeucel for expanded access program

NKGen Biotech said it’s been cleared to launch an expanded access program (EAP) that will allow patients in the U.S. with neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), to access its experimental therapy troculeucel outside clinical trials. EAPs, or compassionate use programs, allow people with serious or life-threatening conditions to receive experimental therapies when no comparable or effective treatment options …